Australia markets close in 47 minutes

Syros Pharmaceuticals, Inc. (SYRS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.61+0.16 (+2.94%)
At close: 04:00PM EDT
5.47 -0.14 (-2.50%)
After hours: 07:28PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-144,493
-164,574
-94,654
-86,558
-84,038
Depreciation & amortisation
1,948
2,252
2,706
3,018
3,035
Stock-based compensation
9,892
10,434
11,410
10,354
10,939
Change in working capital
9,395
5,055
-5,517
-10,602
10,052
Accounts receivable
-
-
0
7
19,993
Accounts payable
8,551
5,133
2,766
48
-1,057
Other working capital
-103,941
-109,979
-124,306
-100,785
-60,700
Other non-cash items
601
650
953
706
2,322
Net cash provided by operating activities
-103,904
-109,707
-123,065
-99,540
-57,364
Cash flows from investing activities
Investments in property, plant and equipment
-
-272
-1,241
-1,245
-3,336
Purchases of investments
0
-50,968
0
-51,408
0
Sales/maturities of investments
64,030
87,017
68,426
0
50,000
Net cash used for investing activities
38,445
37,337
67,185
-52,653
46,664
Cash flows from financing activities
Debt repayment
-12
-65
-291
-265
-241
Common stock issued
-
43,270
119,761
70,337
102,273
Common stock repurchased
-
0
-81
-
-
Other financing activities
-
-
11,438
-41
-207
Net cash used provided by (used for) financing activities
43,250
43,462
131,045
70,511
142,953
Net change in cash
-22,209
-28,908
75,165
-81,682
132,253
Cash at beginning of period
107,851
170,553
95,388
177,070
44,817
Cash at end of period
85,642
141,645
170,553
95,388
177,070
Free cash flow
Operating cash flow
-103,904
-109,707
-123,065
-99,540
-57,364
Capital expenditure
-
-272
-1,241
-1,245
-3,336
Free cash flow
-103,941
-109,979
-124,306
-100,785
-60,700